Key Developments: Trovagene Inc (TROV.W)
6.39USD
5 Jun 2013
$0.01 (+0.16%)
$6.38
$6.50
$6.50
$6.39
200
26
$8.16
$2.16
Latest Key Developments (Source: Significant Developments)
Faruqi & Faruqi, LLP Launches Investigation Against TrovaGene Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, announced that it is investigating the Board of Directors of TrovaGene Inc for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders` approval for an amendment to the 2004 Stock Option Plan. Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on May 29, 2013, the Board of Directors recommends that TrovaGene`s shareholders vote to approve an amendment to increase the number of shares issuable pursuant to the 2004 Stock Plan to 6,000,000 shares from 3,666,667 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of TrovaGene common stock. Full Article
TrovaGene Inc Announces Clinical Collaboration With The University Of Texas MD Anderson Cancer Center
TrovaGene Inc announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's transrenal DNA (TrDNA) detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate (RR); stable disease (SD); progression-free survival (PFS); and overall survival (OS). Results from patients who receive therapy that reflects their BRAF mutation status (e.g., BRAF inhibitors, MEK inhibitors) will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status. Full Article
TrovaGene Inc And Strand Life Sciences Agree To Validate and Commercialize Urine-Based HPV Test in India and South Asia
TrovaGene, Inc. and Strand Life Sciences Pvt Ltd., of Bangalore, India, completed their agreement to validate and commercialize Trovagene's proprietary urine-based Human Papillomavirus (HPV) test for clinical diagnostic and carrier screening use. Trovagene's urine-based HPV test is designed to allow for completely non-invasive HPV carrier screening. Strand's initial target market is an estimated population of over 450 million women between the ages 18 and 65 in India and South Asia. Full Article
TrovaGene, Inc. Announces Issuance Of European Patent For Detection Of Pathogenic Infections
TrovaGene, Inc. announced it has received notice of issuance of European Patent No. 2216416 entitled Methods for Detection of Nucleic Acid Sequences in Urine. This patent pertains to the detection of pathogenic infections from urine specimens and complements previously issued U.S. patents, including the reissued patent RE39920 for the detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples. Other previously issued, related patents include EP0920539 for detection of fetal nucleic acids from maternal urine, and EP1634966 for detection of cancer-specific nucleic acids from a patient's urine sample. Full Article
TrovaGene, Inc. Announces Issuance Of U.S. Patent For NPM Mutants To Diagnose And Monitor Acute Myeloid Leukemia
TrovaGene, Inc. announced that it received notice of U.S. Patent 8,222,370, titled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof. This is the U.S. patent issued around this mutation, and is part of a family of filed patents for Trovagene around NPM. Mutation analysis of nucleophosmin-1 (NPM1) is currently used for the diagnosis, stratification and monitoring of patients with acute myeloid leukemia (AML). Full Article
TrovaGene, Inc. Announces Full Exercise of Over-Allotment Option
TrovaGene, Inc. announced the full exercise of the over-allotment option granted to the underwriters to purchase 172,500 additional units, at a public offering price of $8.00 per unit, in connection with its previously announced underwritten public offering of 1,150,000 units, bringing total gross proceeds from the offering to $10,580,000. announced the full exercise of the over-allotment option granted to the underwriters to purchase 172,500 additional units, at a public offering price of $8.00 per unit, in connection with its previously announced underwritten public offering of 1,150,000 units, bringing total gross proceeds from the offering to $10,580,000. Full Article
TrovaGene, Inc. And Strand Life Sciences Plan Collaboration To Validate And Offer Urine-Based HPV Screening Test In India And South Asia
TrovaGene, Inc. and Strand Life Sciences Pvt Ltd., of Bangalore, India, announced that they have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation (SAARC). Strand intends to establish Trovagene's HPV assay technology in its molecular diagnostic laboratory operations and to perform extended analytical and clinical validation studies in its target markets. The initial validation will assess the diagnostic accuracy using urine as a specimen for HPV testing in various stages of disease progression, ranging from low grade erosions to established cervical cancer. This will be compared to standard cytology and PAP staining as well as a commercially available standard molecular test for the detection of HPV DNA from cervical smears. Strand also intends to explore and validate the clinical utility of HPV DNA testing as a risk indicator and pathological cause of oral cancer in buccal swabs, biopsies and saliva/sputum specimens. Full Article
TrovaGene, Inc. Announces Pricing of Public Offering of 1,150,000 Units and Listing on NASDAQ
TrovaGene, Inc. announced the pricing of an underwritten public offering of 1,150,000 units at an offering price of $8.00 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will begin trading on The NASDAQ Capital Market on May 30, 2012 under the symbol TROVU. Each warrant will have an exercise price of $5.32 per share, will be exercisable upon separation of the units and will expire five years from the closing of the offering. The gross proceeds to Trovagene from this offering are expected to be $9.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 4, 2012. Trovagene has also granted the underwriters a 45-day option to purchase up to an additional 172,500 units to cover over-allotments, if any. Trovagene intends to use the net proceeds from this offering to fund its research and development activities, and for working capital and other general corporate purposes and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated. Trovagene also announced that, effective as of May 30, 2012, its common stock will begin trading on The NASDAQ Capital Market under the symbol "TROVD." In connection with its listing on The NASDAQ Capital Market, Trovagene's common stock will cease trading on the OTC QB. Full Article
Stephen Zaniboni Joins Trovagene, Inc. As Chief Financial Officer
TrovaGene, Inc. announced that Stephen Zaniboni has been named Chief Financial Officer. Full Article
TrovaGene, Inc. Closes Acquisition of CLIA Laboratory Assets
TrovaGene, Inc. announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets. Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
